Caption Management, LLC Arcus Biosciences, Inc. Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $264,217 - $347,593	-19,300 Reduced 39.15%	30,000 $458,000
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $719,287 - $911,064	49,300 New	49,300 $750,000
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $671,500 - $981,500	50,000 New	50,000 $955,000
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $509,099 - $660,900	-30,000 Reduced 50.0%	30,000 $609,000
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $919,296 - $1.33 Million	57,600 Added 2400.0%	60,000 $1.09 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $47,280 - $85,704	2,400 New	2,400 $49,000
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $1.24 Million - $2.72 Million	-72,100 Reduced 70.62%	30,000 $760,000
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $2.95 Million - $4.27 Million	102,100 New	102,100 $3.22 Million
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $769,586 - $1.14 Million	-44,900 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $627,253 - $1.64 Million	44,900 New	44,900 $1.11 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.